

# 2025 Taipei International Breast Cancer Symposium

## Right Choice for Right Patient

Room 701BC, Taipei Nangang Exhibition Center, Hall 2

Sat., October 25, 2025

Time	Topic	Speaker	Moderator
08:00-08:30	Registration		
08:30-08:40	Opening Ceremony	Yen-Shen Lu /Fang-Ming Chen	
Keynote Speech			
08:40-09:00	Right Choice Beyond Survival: How Taiwan is Pioneering Quality and Equity in Breast Cancer Care Through Value-Based Reform	Chung-Liang Shih	Ming-Feng Hou
Session (1) Advancing Therapies for High-Risk Population			
09:00-09:30	Early Onset Breast Cancer: Current Knowledge and Gaps	Kyong Hwa Park	King-Jen Chang
09:30-10:00	Role of Platinum in Adjuvant/Neoadjuvant Treatment in TNBC	Joohyuk Sohn	Shyr-Ming Sheen-Chen
10:00-10:40	Redefining the Role of TKIs in HER2-Positive mBC: From Systemic Control to CNS Penetration	Nancy Lin	Tsu-Yi Chao
10:40-11:00	Coffee Break		
Session (2) Elevating Care in HR+/HER2- Breast Cancer			
11:00-11:40	Navigating the Complexities of Treatment in HR+ HER2-Metastatic Breast Cancer: Tailoring CDK4/6 Inhibitors to Meet Individual Patient Needs	Hope S. Rugo	Hsien-Tang Yeh
11:40-12:20	The Practice of Treating HR+/HER2- Early Breast Cancer is Evolving: Boardening the Impact of CDK4/6 Inhibitors	Peter Fasching	Fang-Ming Chen
Luncheon Symposium (1)			
12:20-13:05	Maximizing Treatment Benefit and Overall Survival in HER2-Negative MBC	Hsu-Huan Chou	Dar-Ren Chen
13:05-13:20	Coffee Break		
13:20-14:00	The Sustainable Efficacy of CDK4/6 Inhibitor in HR+/Her2-Node+ High Risk Early Breast Cancer	Michael Gnant	Shin-Cheh Chen
14:00-14:30	Personalized Neo-Adjuvant Strategies for Hormone Receptor-Positive Early Breast Cancer	Marc Thill	Shigehira Saji
14:30-15:10	Choosing Wisely:TS-1 for HR+ EBC	Kun-Ming Rau	Hsien-Kun Chang
15:10-15:30	Coffee Break		
15:30-16:10	Transforming Treatment Landscape of HR+ mBC: Integrating Genomic Biomarkers to Drive Precision Medicine	Naoto T. Ueno	Chiun-Sheng Huang
16:10-16:50	The Next Wave of Endocrine and Target Therapy for HR+/HER2- Metastatic Breast Cancer	Peter Schmid	Ling-Ming Tseng
Session (3) Expanding the Horizons of HER2+ Metastatic Breast Cancer Treatment			
16:50-17:30	Unlocking the Potential of ADC: Transforming Breast Cancer Outcomes Across HER2 Expression Spectrum (MBC)	Naoto T. Ueno	Yen-Shen Lu
17:30-18:00	Current Status and Emerging Approaches in HER2+ Metastatic Breast Cancer	Giampaolo Bianchini	Ta-Chung Chao

# 2025 Taipei International Breast Cancer Symposium

Right Choice for Right Patient

Room 701BC, Taipei Nangang Exhibition Center, Hall 2

Sun., October 26, 2025

Time	Topic	Speaker	Moderator
Breakfast Symposium			
08:10-08:50	Beyond Cancer-Related Fatigue: Exploring Immunomodulatory Strategies to Reshape Breast Cancer Care	Ming-Shen Dai	Kun-Ming Rau
Session (4) Evolving Role of Breast Surgery			
08:50-09:20	The Surgeon's Role in Locoregional Management of Stage IV Breast Cancer	Mehra Golshan	石川孝
09:20-09:50	Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy	Judy C. Boughey	Jyh-Cherng Yu
09:50-10:05	Coffee Break		
10:05-10:35	Omission of Radiation Therapy Post Breast Conserving Surgery	Boon Chua	Shou-Tung Chen
10:35-11:05	Setting the Standard for the Future of Cancer Surgery	Kelly Hunt	Fiona Tsui-Fen Cheng
Session (5) Innovations in mTNBC: Redefining Frontline Treatment with Immunotherapy and ADCs			
11:05-11:45	Shifting Paradigms in mTNBC - Advancing Sacituzumab Towards the Frontline	Sherene Loi	Chin-Yao Lin
11:45-12:25	A New Era in the Treatment of Metastatic Triple-Negative Breast Cancer: Who, When, and Why to Use Immunotherapy and Antibody-Drug Conjugates	Sung-Bae Kim	Chun-Yu Liu
Luncheon Symposium (2)			
12:25-13:10	Advances in Dual HER2 Inhibition: Shaping the Future of HER2-Positive Breast Cancer Care	Chih-Chiang Hung	Ming-Yang Wang
13:10-13:30	Coffee Break		
Session (6) Advancing Therapeutic Strategies and Accessibility in HER2-Positive Breast Cancer: From Early Management to Metastatic Care			
13:30-14:10	Breaking the Ceiling: Strategies to Reduce Recurrence in HER2+ Early Breast Cancer	Chi-Cheng Huang	Yuan-Ching Chang
14:10-14:50	HER2+ Breast Cancer in the Era of Biosimilars: Optimizing Access with Herzuma	Ching-Ting Wei	Chao-Ming Hung
14:50-15:05	Coffee Break		
15:05-15:45	Optimizing HER2 Management Among Breast Cancer Patients: Role of Trastuzumab in Evolving Therapeutic Paradigms	Paul Cornes	Wen-Hung Kuo
15:45-16:25	From Evidence to Action: Impact of Xgeva in Breast Cancer Bone Metastasis	I-Chen Tsai	Kuo-Ting Lee
16:25-16:45	Award Ceremony		
16:45-17:00	Closing		Yen-Shen Lu

2025 Taipei International Breast Cancer Symposium			
TBCS-GBCC Joint Session: When East Meets West: Navigating Evolving Breast Cancer Care			
Room 701D, Taipei Nangang Exhibition Center, Hall 2			Sat., October 25, 2025
Time	Topic	Speaker	Moderator
10:10-10:30	Axillary management following NAC: Surgical Oncologists’ point of views	Jai Min Ryu	Guo-Shiou Liao Wonshik Han
10:30-10:50	Axillary management following NAC: Medical Oncologists’ point of views	Sung Hoon Sim	
10:50-11:10	Axillary management following NAC: Radiation Oncologists’ point of views	Tzu-Yu Lai	
11:10-11:30	Wrap up: Current guidelines of Axillary management following NAC	Judy C. Boughey	
11:30-12:00	Axillary management following NAC: Surgical Oncologists’ point of views	ALL	
12:10-12:50	Please Proceed to Room 701BC for the Lunch Symposium		
2025 Taipei International Breast Cancer Symposium			
Young Doctors Forum & Young Doctors Debate			
Room 701D, Taipei Nangang Exhibition Center, Hall 2			Sat., October 25, 2025
Young Doctors Forum (YDF)			
14:00-14:05	Opening	Chi-Cheng Huang	
14:05-14:30	Beyond the White Coat: Challenges Facing Young Female Breast Oncologists and How to Address Them	Kelly Hunt	
14:30-14:55	Global Perspectives: Navigating Career Pathways in Breast Cancer Treatment for Young Doctors	Tristen Park	
14:55-15:00	Q&A	ALL	
15:00-15:05	Break		
Young Doctors Debate (YDD)			
15:05-15:45	In this scenario, should ALND be omitted based on current evidence, or is completion ALND still necessary to ensure adequate staging and local control?	YDF Invitees	Chiao Lo
15:45-16:25	Should adjuvant chemotherapy be avoided in this patient given her low recurrence score, despite the presence of nodal micrometastasis?		Chun-Yu Liu
16:25-16:30	QA & Closing	Jeong Eon Lee	
16:30-	Group Photo	ALL	

## 2025 Taipei International Breast Cancer Symposium

### Mini-Symposium

Room 701A, Taipei Nangang Exhibition Center, Hall 2

Sun., October 26, 2025

Time	Topic	Speaker	Moderator
09:35 -10:15	TBD	Chih-Hao Huang	Chih-Chiang Hung
10:15-10:55	New Horizons in First-Line Management of HR+ mBC with PIK3CA Mutation	Shih-Che Shen	Yan-Ang Chen
10:55-11:35	Immunotherapy in Early TNBC: Evolving Evidence, Maximizing Benefit Through Thoughtful Patient Selection	Han-Fang Cheng	Ling-Ming Tseng
11:35-12:15	Suture Scaffold Technique in Breast-Conserving Surgery: Safety, Cosmetic Outcomes, and Lessons from Over 2,000 Cases	Reiko Mitsueda	Chen-Hsiang Chang
12:15-13:10	Luncheon Symposium Treatment Strategies and Sequencing After ET + CDK4/6i for Patients With ER+/HER2- Metastatic Breast Cancer	Soo Chin Lee	Wei-Pang Chung
13:10-13:50	Not all CDK4/6i are created equal: Optimizing HR+ HER2- Metastatic Breast Cancer Treatment Outcomes	Michael Gnant	Ching-Hung Lin
13:50-14:30	Oncofertility Needs and Supportive Care for Breast Cancer Women in Reproductive Age: The Experience from Hope Foundation for Cancer Care in Taiwan	Shiuyu Katie C. Lee	Yao-Jen Chang
14:30-15:10	Survivorship in Breast Cancer: Physical Activity and Alcohol Consumption and Breast Cancer	Tristen Park	Liang-Chih Liu
15:10-15:50	Cardio-Oncology at NCKUH: Breast Cancer and Cardiotoxicity - Progress and Future Directions	Yu-Ling Hsu	Chin-Sheng Hung